BetterLife Pharma (BETRF)

BetterLife Pharma (BETRF), is an early-stage Canadian psychedelic drug development company. The companies lead drug candidate BETR-001 is being developed for headache disorders. BETR-001 is a fully non-hallucinogenic derivative of LSD. They expect to commence phase 1A and 1B clinical trials for cluster headache and migraine, in the first quarter of 2027, pending the public offering of US $100 million, scheduled by 9/15/2026.  The company website is here Betterlifepharma.com.  

Some important timelines from the past.

08/28/26: $100 million capital raise public offering, pending. Public Offering
05/13/26: Doug Drysdale as Executive Chairman and Director. Drysdale appointment
01/14/25:  BETR-001 Composition of Matter Patent Granted 2042.  BETR-001 Patent
11/15/23:  US Patent Office publishes BETR-001. Published BETR-001
03/28/23: Published study of non-hallucinogenic LSD.  Non-hallucinogenic LSD
09/27/21:  Files patent for TD-0148A, 2-bromo-LSD (BETR-001). Patent Filed
12/20/20: All-stock transaction, acquired 100% of psychedelic biotech firm Transcend Biodynamics, gaining the rights to BOL-148, a proprietary LSD derivative, now referred to as BETR-001. Acquires Transcend Biodynamics 

In 2010, a study utilizing BOL-148 (non-hallucinogenic form of LSD) was initiated for cluster headache participants. This  should be viewed as proof of concept study, with caveats. The general result of the study, was that all five participants had a response to the therapeutic. The link to that study is here. Cluster Headache Clinical Trial

Financial Statistics: 

- 5M in cash
- 170 million diluted shares outstanding
- 37 million market cap

Intellectual Property:

• BETR-001 - Patent expected to expire into 2042

Timeline Catalyst:

• BETR-001: Begin a phase 1A, 1B clinical trial,  first quarter of 2027

BetterLife Pharma (BETRF) is a clinical stage biotech company focused on the unmet medical need of cluster headaches and migraine. The stock is priced at $.23 cents per share (penny stock). There are risks to investing in this early stage drug development company, and return of capital invested is not a guarantee. 

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

GOLD & Technical Moving Averages

Gold advanced higher last week, and technically has cleared some important moving averages. Moving averages are technical indicators that highlight longer term trends or cycles by smoothing out the data, over a specific period of time. The popular moving averages include the simple 50, 100, and 200 day moving average. Below is a daily chart of $GOLD, showing technical strength by trading above those 50, 100, and 200 moving averages. Thank you for reading. 

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

Definium Therapeutics - GAD Phase 3 Results

We previously wrote about the psychedelic drug development company Definium. The company released top-line phase 3 clinical results for GAD (Generalized Anxiety Disorder), from their trial named VOYAGE this morning. The other psychedelic company attempting to address this unmet need is Helus Pharma, who already released phase 2a clinical data earlier this year, with psychedelic deuterated DMT. Although it's difficult to compare clinical data from two different trials, below is Helus Pharma's phase 2a (6 and 24 Weeks) along side Definium's phase 2b and just released phase 3 results. 

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

Nuvation Bio 2nd Quarter Results

Nuvation Bio (NUVB) is addressing unmet medical need in cancer with lead approved drug Ibtrozi, and clinical testing Safusidenib for high grade glioma. The company released second quarter financial results before market open today. The company is gaining traction with new patients for lead drug Ibtrozi. The drug has been FDA approved for ROS1 NSCLC since June of 2025, and revenues are starting to climb. Some key highlights from the second quarter results below. 

- $31.7 million in second quarter total revenue

- $23.2 Ibtrozi US revenue

- 30% quarter over quarter TKI naive growth

- License and collaboration revenue of $8.5 million

- Convertible senior notes raised $279 million in Q2

- Cash equivalents of $697 million

- Current Market cap of $2.3B

The net loss was $62.8 million for the quarter, or (.18) per share.

Second drug Safusidenib is currently in phase 3 testing with the SIGMA trial for high grade glioma, with expected completion around 2029. The trial can be viewed here NCT05303519. 

All prior Nuvation posts can be viewed here Nuvation Bio Posts. Thank you for reading.

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

HELUS Pharma: An Update

A reminder that Helus Pharma was formerly Cybin and changed the name in early 2026.

 

The psychedelic space is now under consolidation, as ATAI today has announced LLY to Acquire ATAI, for up to $3.8 billion consideration. This post is regarding Helus Pharma, ticker symbol (HELP), and the prospects of them being acquired in the future.

Helus's (HELP) main asset is HLP003, which is a deuterated form of psilocybin in phase 3 clinical trials for adjunctive MDD. The top line readout for the 1st phase 3 APPROACH is scheduled to be released by the end of 2026. The second phase 3 EMBRACE is scheduled to complete in 2027, and the company will seek FDA approval once completing.

 

There are a number of larger companies already approved for adjunctive MDD that might find interest in obtaining Helus's asset HLP003, as the patent runs until 2041. 

Here is a list in any order of the larger companies already approved for aMDD which might see value in obtaining a quick acting psychedelic drug, with a long patent runway of 2041.

AbbVie: Drug Vraylar is approved for aMDD with patent expiring in 2030. Vraylar is a valuable asset for AbbVie and is producing total annual revenue of $3.6 billion for the company. Revenue is not broken out per indication as Vraylar has been approved for adjunctive MDD, Bi-Polar Depression and Schizophrenia. The company has already expressed an interest in the psychedelic field, as they previously purchased Gilgamesh Pharmaceuticals psychedelic drug compound Bretisilocin here, Gilgamesh-Pharmaceutical.

Johnson & Johnson: January 13th 2025 is the date that J&J made the acquisition of Intra-Cellular. After that acquisition, lead Intra-Cellular drug Caplyta was approved for aMDD in November 2025. The patent expiration for composition of matter expires in 2028, with additional patents extending out to 2034 and 2040. J&J is currently testing a deuterated form of Caplyta known as ITI-1284 in two GAD clinical trials, with completion estimated to be mid 2027.

Otsuka/Lundbeck: Rexulti has been approved for aMDD since 7/10/2015, with patent expiring in 2026.  

Definium Therapeutics: DFTX is a mid-cap psychedelic stock with a $6.2 billion market cap, and looks like the best bet to go it alone in the psychedelic space, as they have substantiated clinical data for GAD, and MDD with an abundance of cash on hand. Adding a potential approval of adjunctive MDD to their offering could make them a psychedelic powerhouse. Helus also has in their pipeline HLP004 for GAD, which might also appeal to Definium by eliminating competition from their main asset DT120, or potentially modifying clinical development of HLP004, to bring a second GAD option to patients. 

I would expect AbbVie and Definium Therapeutics, to be most interested in Helus Pharma as a potential buyout. The patent for Vraylar is expiring in 2030, which means generics can proceed with gaining access to selling a generic version. AbbVie may start seeking revenue replacement for the future patent cliff.

An acquisition of Helus Pharma would not be too complicated, as the company is small with 60 million shares outstanding, additional warrants outstanding, and little debt. 

It will be interesting to see how this sector plays out over the next year. Chart below of the five major psychedelic stocks and their year-to-date performance. Thank you for reading. 

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

Psychedelic Sector Update #2

A quick valuation update of the psychedelic sector. Listed are the five most advanced companies pursuing psychedelic therapies. 

NUVB: Nuvation Bio - Update #12

Nuvation Bio has one commercial asset Ibtrozi for ROS1 NSCLC. Their second asset Safusidenib for high-grade glioma, is in clinical trials which can be found here Clinical Trials. The latest positive news from Nuvation comes as they have received net proceeds of $277.6 million, from an oversubscribed convertible notes offering due 2032. Positives from the just completed notes offering below. 

• Retired older, high interest debt of $55.8 million
• $17.1 million used for capped call options, hedge to $10.458 
• At present, is non-diluting to shareholders
• Added new cash of around $205 million after all deductions
• Multi-year cash runway now available

The new cash infusion will be used to fund clinical development, and general corporate purposes. Weekly chart of Nuvation below, thank you for reading.

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

NMRA: Neumora Therapeutics

Neumora Therapeutics, an early-stage neuroscience drug development company, focuses on three key areas, alzheimer's agitation, schizophrenia and obesity. The companies three lead candidates, will have early stage clinical trial read-outs, by the end of 2026.

Financial Statistics: 

- $147 million cash
- 180 million diluted shares outstanding
- 270 million market cap

Intellectual Property:

• NMRA - 511 Alzheimer's Agitation, Expected to expire into 2042
• NMRA - 898 Schizophrenia, Expected to expire in 2044
• NMRA - 215 Obesity, Expected to expire in 2043

Timeline Catalyst:

• NMRA-511: Multiple ascending dose completion in the fourth quarter 2026
• NMRA-898: Phase 1 data 2H of 2026
• NMRA-215: Start clinical trials by end of 2026

Neumora is a clinical stage biotech company focused on three areas of unmet need. The stock is priced at $1.51 per share (penny stock). There are many risks to investing in this company. 

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

NUVB: Nuvation Bio - Update #11

All of Nuvation Bio's previous posts, can be found here Nuvation Posts.  The company is addressing the unmet need of ROS1 and high grade glioma, with two unique drugs. 

From recent investor conferences that the company has participated, we were given some updated pipeline information. Two updates of interest, include the following for second drug candidate safusidenib. 

1. The 40 patient Grade 3 oligodendroglioma which is part of the SIGMA study NCT05303519, has objective response rate as the primary endpoint. The goal of achieving a 20% + response rate in this population, would be seen as positive over standard of care chemotherapy for these patients. The study will be conducted as an Open-Label single arm. 

 2. Yet To Be Announced: Safusidenib treatment for those patients that have been on approved drug vorasidenib, and over time have failed. The endpoint again would be objective response rate, with a goal of achieving 20%. 

 

Both trials could benefit from ORR as a quicker endpoint read-out, a smaller number of patients, with potential 2027 data. The daily chart of Nuvation below displays a consolidation range over the past two and a half months. The high of $5.29 and low support at $4.05. This consolidation chart pattern has the potential to have a strong breakout.  

Disclaimer: This stock, or any other stock referenced on this site, is for educational purposes only, not personalized advice. Consult with your investment advisor professional, prior to buying stocks, precious metals, commodity's, or crypto.

Gold and Oil - Negative Correlation Updated

In response to the current correlation. Yes, the negative correlation of gold and oil is holding up strong today. Oil (brent oil) has fallen in price today, and gold has accelerated higher. The current negative correlation is at -0.97.

NUVB: Nuvation Bio - Update #10

Nuvation Bio is addressing unmet medical need in cancer with lead approved drug Ibtrozi, and clinical testing Safusidenib for high grade glioma. The company released first quarter financial results after the close of trading today. The company is gaining traction with new patients for lead drug Ibtrozi. The drug has been FDA approved for ROS1 NSCLC since June of 2025. Some key highlights from the first quarter results below. 

- 18.5 million in first quarter Ibtrozi revenue

- Greater than 50% of new patients were early line diagnosis

- China / Japan royalty revenue of $1.7 million

- Cash equivalents of $533.7 million

- Current Market cap of $1.5B

Essentially it was a breakeven quarter for Nuvation due to a one time collaboration payment from European partner Eisai, which combined with quarterly revenue, covered the research and SGA costs for the quarter. 

Second drug Safusidenib is currently in phase 3 testing with the SIGMA trial for high grade glioma, with expected completion around 2029. The trial can be viewed here NCT05303519. 

All prior Nuvation posts can be viewed here Nuvation Bio Posts. Thank you for reading. 

Auvelity FDA Approval for Alzheimer's Disease Agitation

We first wrote about the unmet need for ADA here Agitation In Alzheimer's Disease - An Unmet Need. Axsome Therapeutics was given approval for the indication of Alzheimer's Disease Agitation (ADA), with drug Auvelity from the FDA. This addresses an unmet need, and the first non-antipsychotic approval for ADA. This is the second approval for Auvelity, as it was granted approval for MDD in 2022. Axsome currently has three in-house drug approvals as follows. 

• Auvelity for MDD  8/19/22
• Symbravo for Acute Migraine  1/30/25
• Auvelity for ADA  4/30/26

The stock as expected, had a positive reaction to the news per chart below. Thank you for reading.